Close

Cantor Fitzgerald Assumes Cidara Therapeutics (CDTX) at Overweight, Sees Underappreciated Sales Potential

June 26, 2017 2:45 AM EDT Send to a Friend
Cantor Fitzgerald assumes coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Overweight rating and a price target of $15.00.Analyst Louise ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login